Glucagon-like peptide-1 analogues in adults with type 2diabetes mellitus for glycaemic control

Abstract

This article has highlighted the position of GLP-1 therapy in the management of T2DM. Essential points to remember are that GLP-1 analogues may be beneficial for people withASCVD and/or obesity, alongside T2DM as this drug class has shown benefit inimproving cardiovascular outcomes and reducing weight, both of which we know areintrinsically linked to T2DM. Pharmacists can play a vital role in providing individualised care for people with diabetesthrough the consideration, initiation and subsequent titration of GLP-1 analogues.Pharmacists can discuss with patients the different options in the class, considering bothdaily and weekly injectable therapies as well as oral semaglutide, ensuring the choice ofGLP-1 analogue is patient-specific and appropriate. In addition, pharmacists can provide appropriate injection technique counselling or ensurethat oral counselling is undertaken at the point of prescribing; provide a review of peopleon GLP-1 therapy; and provide education on common side effects and actions to take ifthese occur.